Blood
01 Jan 2013
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and…
Infections
01 Jan 2013
Efficacy and safety of Pegasys plus Copegus in patients with chronic Hepatitis C who are unable to tolerate or who do not respond to 12 weeks of therapy with PEG-Intron plus Rebetol/Ribavirin.
The objective of this study is to investigate if patients with Chronic Hepatitis C virus who were unable to tolerate or did not respond to 12 weeks of PEG-Intron plus Rebetol/Ribavirin therapy can be safely initiated on Pegasys plus Copegus therapy and tolerate and complete a full course (36 to…
Infections
01 Jan 2013
Prophylactic Heparin during Xigris Treatment of High-Risk Severe Sepsis
The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during Xigris infusion in the treatment of severe sepsis in the adult. Official Title Conditions Sepsis Study Type Interventional Study Design Treatment Further Details Study Start Eligibility & Criteria Inclusion Criteria- Must…
Mental Health
01 Jan 2013
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia
Key objectives of this clinical study are to: – Determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine – Evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine – Evaluate different doses of IM olanzapine depot to identify the best dose(s)…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Neuroendocrine Tumors
The primary objective of the study is to determine the efficacy and safety of SU011248 as a treatment for patients with advanced unresectable neuroendocrine tumor; however, CURRENTLY ONLY RECRUITING FOR PATIENTS SPECIFICALLY WITH PANCREATIC ISLET CELL TUMORS. Official Title Phase II Study of SU011248 in Patients with Neuroendocrine Tumors; however,…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel. Official Title A Phase 2 Efficacy and Safety Study of SU011248 in Patients with Metastatic Non-Small Cell Lung…
Bone
01 Jan 2013
Ibandronic Acid versus Zoledronic Acid in Cancer Patients with Skeletal Metastases Experiencing Moderate to Severe Pain
The purpose of the study is to investigate a new therapy for treating bone pain that results from cancer that has spread to the bones. The study compares treatment with ibandronic acid against treatment with another drug, zoledronic acid (a drug similar to ibandronic acid) to determine which drug is…
Hormones
01 Jan 2013
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients with Thyroid or Pituitary Abnormalities
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities. Normal thyroid gland function depends on proper chemical signaling between the thyroid gland, the hypothalamus (the part of the brain where…
Cancer
01 Jan 2013
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: Randomized clinical trial to study the effectiveness of celecoxib in managing pain, weight loss, and weakness in patients with advanced cancer. Official Title…
